Oruka Therapeutics Book Value Per Share Growth & History (ORKA)
Oruka Therapeutics's book value per share was $9.69 for fiscal 2025.
View full Oruka Therapeutics company overviewOruka Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $9.69 | -$0.44 | −4.39% |
| 2024 | 2024-12-31 | $10.13 | $7.58 | +296.82% |
| 2023 | 2023-12-31 | $2.55 | -$0.34 | −11.72% |
| 2022 | 2022-12-31 | $2.89 | -$0.65 | −18.36% |
| 2021 | 2021-12-31 | $3.54 | -$1.33 | −27.30% |
| 2020 | 2020-12-31 | $4.87 | $0.10 | +2.06% |
| 2019 | 2019-12-31 | $4.77 | -$3.02 | −38.78% |
| 2018 | 2018-12-31 | $7.80 | -$7.91 | −50.35% |
| 2017 | 2017-12-31 | $15.71 | -$28.28 | −64.29% |
| 2016 | 2016-12-31 | $43.99 | -$31.72 | −41.90% |
| 2015 | 2015-12-31 | $75.71 | -$12.11 | −13.79% |
| 2014 | 2014-12-31 | $87.82 | -$37.34 | −29.84% |
| 2013 | 2013-12-31 | $125.16 | -$12.52 | −9.10% |
| 2012 | 2012-12-31 | $137.68 | -$218.01 | −61.29% |
| 2011 | 2011-12-31 | $355.69 | -$223.72 | −38.61% |
| 2010 | 2010-12-31 | $579.42 | — | — |
Oruka Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $18.25 | $9.15 | +100.61% |
| Q1 2026 | 2026-03-31 | $9.70 | $0.04 | +0.40% |
| Q4 2025 | 2025-12-31 | $9.69 | -$0.44 | −4.39% |
| Q3 2025 | 2025-09-30 | $10.00 | $0.22 | +2.23% |
| Q2 2025 | 2025-06-30 | $9.10 | $11.10 | — |
| Q1 2025 | 2025-03-31 | $9.66 | $10.15 | — |
| Q4 2024 | 2024-12-31 | $10.13 | $7.58 | +296.82% |
| Q3 2024 | 2024-09-30 | $9.78 | $7.15 | +271.27% |
| Q2 2024 | 2024-06-30 | -$2.00 | -$4.72 | — |
| Q1 2024 | 2024-03-31 | -$0.49 | -$3.30 | — |
| Q4 2023 | 2023-12-31 | $2.55 | -$0.34 | −11.72% |
| Q3 2023 | 2023-09-30 | $2.63 | -$0.33 | −11.14% |
| Q2 2023 | 2023-06-30 | $2.72 | -$0.40 | −12.73% |
| Q1 2023 | 2023-03-31 | $2.81 | -$0.51 | −15.45% |
| Q4 2022 | 2022-12-31 | $2.89 | -$0.65 | −18.36% |
| Q3 2022 | 2022-09-30 | $2.97 | -$0.96 | −24.51% |
| Q2 2022 | 2022-06-30 | $3.12 | -$1.13 | −26.54% |
| Q1 2022 | 2022-03-31 | $3.33 | -$1.25 | −27.27% |
| Q4 2021 | 2021-12-31 | $3.54 | -$1.33 | −27.30% |
| Q3 2021 | 2021-09-30 | $3.93 | -$1.51 | −27.71% |
| Q2 2021 | 2021-06-30 | $4.25 | -$0.30 | −6.53% |
| Q1 2021 | 2021-03-31 | $4.57 | $0.62 | +15.62% |
| Q4 2020 | 2020-12-31 | $4.87 | $0.10 | +2.06% |
| Q3 2020 | 2020-09-30 | $5.43 | -$0.09 | −1.56% |
| Q2 2020 | 2020-06-30 | $4.54 | -$1.77 | −28.01% |
| Q1 2020 | 2020-03-31 | $3.96 | -$2.70 | −40.60% |
| Q4 2019 | 2019-12-31 | $4.77 | -$3.02 | −38.78% |
| Q3 2019 | 2019-09-30 | $5.52 | -$4.13 | −42.79% |
| Q2 2019 | 2019-06-30 | $6.31 | -$5.32 | −45.73% |
| Q1 2019 | 2019-03-31 | $6.66 | -$7.64 | −53.43% |
| Q4 2018 | 2018-12-31 | $7.80 | -$7.91 | −50.35% |
| Q3 2018 | 2018-09-30 | $9.65 | -$12.34 | −56.12% |
| Q2 2018 | 2018-06-30 | $11.63 | -$14.61 | −55.67% |
| Q1 2018 | 2018-03-31 | $14.30 | -$21.09 | −59.60% |
| Q4 2017 | 2017-12-31 | $15.71 | -$28.28 | −64.29% |
| Q3 2017 | 2017-09-30 | $21.98 | -$30.50 | −58.12% |
| Q2 2017 | 2017-06-30 | $26.24 | -$35.09 | −57.22% |
| Q1 2017 | 2017-03-31 | $35.39 | -$33.34 | −48.51% |
| Q4 2016 | 2016-12-31 | $43.99 | -$31.72 | −41.90% |
| Q3 2016 | 2016-09-30 | $52.49 | -$29.24 | −35.78% |
| Q2 2016 | 2016-06-30 | $61.33 | -$25.88 | −29.68% |
| Q1 2016 | 2016-03-31 | $68.74 | -$3.35 | −4.64% |
| Q4 2015 | 2015-12-31 | $75.71 | -$12.11 | −13.79% |
| Q3 2015 | 2015-09-30 | $81.73 | -$20.77 | −20.26% |
| Q2 2015 | 2015-06-30 | $87.21 | -$28.65 | −24.73% |
| Q1 2015 | 2015-03-31 | $72.08 | -$57.11 | −44.21% |
| Q4 2014 | 2014-12-31 | $87.82 | -$37.34 | −29.84% |
| Q3 2014 | 2014-09-30 | $102.50 | -$72.90 | −41.56% |
| Q2 2014 | 2014-06-30 | $115.87 | -$134.15 | −53.66% |
| Q1 2014 | 2014-03-31 | $129.19 | -$1.77 | −1.35% |
| Q4 2013 | 2013-12-31 | $125.16 | -$12.52 | −9.10% |
| Q3 2013 | 2013-09-30 | $175.40 | $11.17 | +6.80% |
| Q2 2013 | 2013-06-30 | $250.01 | $46.04 | +22.57% |
| Q1 2013 | 2013-03-31 | $130.96 | -$139.34 | −51.55% |
| Q4 2012 | 2012-12-31 | $137.68 | -$218.01 | −61.29% |
| Q3 2012 | 2012-09-30 | $164.24 | -$247.83 | −60.14% |
| Q2 2012 | 2012-06-30 | $203.97 | -$338.46 | −62.40% |
| Q1 2012 | 2012-03-31 | $270.31 | — | — |
| Q4 2011 | 2011-12-31 | $355.69 | -$223.72 | −38.61% |
| Q3 2011 | 2011-09-30 | $412.06 | — | — |
| Q2 2011 | 2011-06-30 | $542.43 | — | — |
| Q4 2010 | 2010-12-31 | $579.42 | — | — |
Oruka Therapeutics book value per share trends
Over the last five fiscal years, Oruka Therapeutics's book value per share increased from $4.87 to $9.69, a change of $4.81. The latest reported quarter, Q2 2026, shows $18.25.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Oruka Therapeutics source filings ↗